I offer this from Pete Abraham’s Twitter feed, but I’m not trying to single Pete out. Many people have made such comments this morning, so I use his as mere example:
- The could lose the suit because anyone can lose any suit;
- They could lose the suit in such a way that actually creates legal precedent that makes it harder to go after drug users or otherwise misbehaving players;
- Win or lose they will cost themselves millions if not tens of millions in legal fees;
- If they lose they have a player under contract who is alienated from the team to the nth degree, making life much harder;
- Win or lose their employees will miss tons of work for depositions, preparation and the like;
- Win or lose a lawsuit may cause potential free agents to avoid the Yankees because they believe, rationally or not, that the team is just waiting to pounce on its players in the event they make any missteps.
- Mostly, though, because lawsuits are awful;
As for winning or losing: there is a means for a PED-user to have his contract voided: being disciplined three times, which leads to a lifetime ban. For the Yankees to attempt to void the deal now is the equivalent of that, financially speaking, and I’d have a hard time seeing a court or an arbitrator agree that they can simply leapfrog over two suspensions like that to cost A-Rod the $114 million left on his deal.
If there is discipline, it will be a 50-game suspension. And it may not happen at all. Let’s not jump the gun here.
According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.
A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.
Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.
Espinosa will reach free agency after the 2017 season.
The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.
The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.
Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.
Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.